Brewis Neil 4
4 · F-star Therapeutics, Inc. · Filed Nov 24, 2020
Insider Transaction Report
Form 4
Brewis Neil
Chief Scientific Officer
Transactions
- Award
Common Stock
2020-11-20+19,844→ 19,844 total - Award
Stock Option (right to buy)
2020-11-20+6,307→ 6,307 totalExercise: $0.08Exp: 2029-05-07→ Common Stock (6,307 underlying) - Award
Stock Option (right to buy)
2020-11-20+70,312→ 70,312 totalExercise: $0.08Exp: 2030-07-01→ Common Stock (70,312 underlying)
Footnotes (5)
- [F1]Represents shares of common stock of F-star Therapeutics, Inc. (formerly Spring Bank Pharmaceuticals, Inc.) (the "Issuer") issued by the Issuer in the share exchange transaction that was completed on November 20, 2020 pursuant to the Share Exchange Agreement, dated as of July 29, 2020, by and among the issuer, F-star Therapeutics Limited ("F-star") and the holders of F-star shares, options, RSUs, and notes convertible into F-star shares.
- [F2]The exercise price was originally in Pound Sterling and converted to U.S. Dollars using a conversion price of 0.844 according to Thomson Reuters.
- [F3]This option was issued in replacement of an option to purchase shares of F-star Therapeutics Limited.
- [F4]So long as Participant remains continuously a Service Provider 28% of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, May 7, 2019, and 2% of the total number of Shares under Award shall vest monthly thereafter
- [F5]Twenty-five per cent (25%) of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of Shares under Award shall vest monthly thereafter, provided in each case that the Participant remains a Service Provider continuously from the Vesting Commencement Date to the relevant date.